PMID- 25442285
OWN - NLM
STAT- MEDLINE
DCOM- 20150330
LR  - 20171116
IS  - 1618-095X (Electronic)
IS  - 0944-7113 (Linking)
VI  - 21
IP  - 12
DP  - 2014 Oct 15
TI  - Baicalein protects against hypertension associated with diabetes: effect on 
      vascular reactivity and stiffness.
PG  - 1742-5
LID - S0944-7113(14)00327-4 [pii]
LID - 10.1016/j.phymed.2014.08.012 [doi]
AB  - The present work investigated the possible protective effect of baicalein, a 
      natural lipoxygenase enzyme inhibitor, on both insulin deficiency (ID) and 
      insulin resistance (IR)-induced macro-vascular impairment. ID and IR were induced 
      by STZ or fructose for 8 or 12 weeks respectively while baicalein was 
      administered in the last six weeks. Blood pressure (BP) was recorded and isolated 
      aorta reactivity to phenylephrine (PE) and acetylcholine (ACh) were studied. 
      Blood levels of glucose, insulin, advanced glycation end products (AGEs) and 
      tumour necrosis factor-alpha (TNF-alpha) were determined. Aortic nuclear transcription 
      factor-kappaB (NF-kappaB) activation was assessed. Both models resulted in elevated BP, 
      increased vasoconstriction and impaired relaxation KCl, elevated TNF-alpha and AGEs, 
      NF-kappaB activation, marked infiltration of leukocytes in the adventitia, pyknosis 
      of endothelial cells and marked collagen deposition. Baicalein ameliorated 
      elevations in BP in models, prevented exaggerated vasoconstriction IR model and 
      improved relaxation in ID model. Baicalein reduced AGEs and TNF-alpha level, 
      decreased NF-kappaB activation and inhibited histopathological changes in both 
      models. Baicalein offsets the hypertensive and the vascular impairment associated 
      with both diabetic models via ameliorating functional and structural derangements 
      of blood vessels.
CI  - Copyright (c) 2014 Elsevier GmbH. All rights reserved.
FAU - El-Bassossy, Hany M
AU  - El-Bassossy HM
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz 
      University, Jeddah, Saudi Arabia; Department of Pharmacology and Toxicology, 
      Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Electronic address: 
      helbassossy@kau.edu.sa.
FAU - Hassan, Noura Ahmed
AU  - Hassan NA
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig 
      University, Zagazig, Egypt.
FAU - Mahmoud, Mona Fouad
AU  - Mahmoud MF
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig 
      University, Zagazig, Egypt.
FAU - Fahmy, Ahmed
AU  - Fahmy A
AD  - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig 
      University, Zagazig, Egypt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140919
PL  - Germany
TA  - Phytomedicine
JT  - Phytomedicine : international journal of phytotherapy and phytopharmacology
JID - 9438794
RN  - 0 (Flavanones)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 49QAH60606 (baicalein)
SB  - IM
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Diabetes Mellitus, Experimental/*complications/physiopathology
MH  - Flavanones/*pharmacology
MH  - Glycation End Products, Advanced/metabolism
MH  - Hypertension/complications/*drug therapy/physiopathology
MH  - Insulin Resistance
MH  - Male
MH  - NF-kappa B/metabolism
MH  - Rats, Wistar
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Vasoconstriction/drug effects
OTO - NOTNLM
OT  - Baicalein
OT  - Complication
OT  - Diabetes
OT  - Rat
EDAT- 2014/12/03 06:00
MHDA- 2015/03/31 06:00
CRDT- 2014/12/03 06:00
PHST- 2014/05/18 00:00 [received]
PHST- 2014/07/25 00:00 [revised]
PHST- 2014/08/24 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/03/31 06:00 [medline]
AID - S0944-7113(14)00327-4 [pii]
AID - 10.1016/j.phymed.2014.08.012 [doi]
PST - ppublish
SO  - Phytomedicine. 2014 Oct 15;21(12):1742-5. doi: 10.1016/j.phymed.2014.08.012. Epub 
      2014 Sep 19.